Company / Cash & Equivalents
Stryker Corporation Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$4.0B
FY2025
5-year range
$1.8B / $4.0B
FY2021-FY2025
Trend
+9.8%
vs FY2024
Sector context
#12 of 148
Health Care
What the data says
Among 148 Health Care companies, Stryker Corporation is in the top 8% for cash & equivalents. Cash & Equivalents has increased for 3 consecutive years, from $1.8B in FY2022 to $4.0B in FY2025.
Based on SEC 10-K filings.
$4.0B in FY2025 with a 5-year CAGR of +6.4%. Top quartile in the Health Care sector.
Improved from $3.0B to $4.0B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +29.6%
- 5-Year CAGR
- +6.4%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 148This company $4.0B Sector average $1.2B
▼
+240.8% above sector average
Key checks
Key Insights
- Stryker Corporation's cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of +6.4%, indicating consistent growth.
- In FY2025, cash & equivalents increased 9.8% year-over-year.
- Ranks #12 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.0B | +9.8% |
| FY2024 | $3.7B | +22.9% |
| FY2023 | $3.0B | +61.1% |
| FY2022 | $1.8B | -37.4% |
| FY2021 | $2.9B | +0.0% |
| FY2020 | $2.9B | -32.1% |
| FY2019 | $4.3B | +30.8% |
| FY2018 | $3.3B | -1.9% |
| FY2017 | $3.4B | +88.2% |
| FY2016 | $1.8B | -46.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026